Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 6, 2007, Pages 419-422

  Huang, T D ^a   Almpanis, C ^a   Denis, O ^b   Nonhoff, C ^b   Delaere, B ^a   Glupczynski, Y ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; FUSIDIC ACID; GENTAMICIN; KANAMYCIN; MINOCYCLINE; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

AGED; ANAMNESIS; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BLOOD CULTURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEART SURGERY; HIP PROSTHESIS; HUMAN; INTERVERTEBRAL DISK DEGENERATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MITRAL VALVE REPLACEMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SEPSIS; WOUND INFECTION;

AGED, 80 AND OVER; HUMANS; MALE; METHICILLIN RESISTANCE; RECURRENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 34249863299     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0297-1     Document Type: Article

References (11)

1. Ruef C (2004) Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32:315-327
2. Nonhoff C, Denis O, Struelens MJ (2005) Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clin Microbiol Infect 11:214-220
3. Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Approved standard MS100-S16. CLSI (formerly NCCLS), Wayne, PA
4. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D (2001) Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39:2439-2444
5. Harmsen D, Claus H, Witte W, Rothganger J, Claus H, Turnwald D, Vogel U (2003) Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 41:5442-5448
6. Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, De Mendonca R, Struelens MJ (2006) In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother 50:2680-2685
7. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A (2003) Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 41:1687-1693
8. Boyle-Vavra S, Berke SK, Lee JC, Daum RS (2000) Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 44:272-277
9. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC, Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 36:429-439
10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering Jr RC, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398-2402
11. Goldstein FW, Kitzis MD (2003) Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin Microbiol Infect 9:761-765